Tg Therapeutics (TGTX US)

Analysis

Health Care • United States

TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies, specifically, relapsed and refractory non-Hodgkins lymphoma.

Refresh

Company Presentation • 10 Jan 2024 08:30

J.P. Morgan 42nd Annual Healthcare Conference 2024

Company Presentation • 14 Jan 2026 05:30

44th Annual J.P. Morgan Healthcare Conference

Company Presentation • 14 Jan 2025 08:30

43rd Annual J.P. Morgan Healthcare Conference 2025

Company Presentation • 29 Dec 2022 21:30

FDA Announcement

No more presentations

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00